Press Release & Publications

2022-06-20

Allgenesis Announces First Patient Dosed in the U.S. for the Phase 1b trial Evaluating AG-80308 for the Treatment of Dry Eye Disease

Taipei, Taiwan/June 20th, 2022 Allgenesi […]

2022-06-13

Allgenesis Announces First Patient Enrollment in a FIH Phase 2a Trial of AG-73305 for the Treatment of Diabetic Macular Edema

Taipei, Taiwan/June 13th, 2022 All […]

2022-03-31

Allgenesis Announces FDA Clearance of the IND for AG-73305 for the Treatment of Diabetic Macular Edema

Taipei, Taiwan/ March 31st, 2022 Allgene […]

2022-02-28

Allgenesis Receives Notice of Grant of Patent for Fusion Protein of VEGF Trap and Disintegrin in China

February 28th, 2022 Allgenesis Biotherap […]

2021-11-25

Allgenesis Biotherapeutics Inc. – U.S. Patent Granted for Fusion Protein of VEGF Trap and Disintegrin

November 25th, 2021 Allgenesis Biotherap […]

2021-10-26

Allgenesis to present AG-73305 at Bio Partnering APAC Summit 2021 in Shanghai

Taipei, Taiwan/ October 26th, 2021 Allge […]